Does NAD+ really decline with age?

Yes — that observation is reasonably well replicated across tissues and species.

What causes the decline?

Covarrubias 2020 reported that senescent cells drive it by increasing CD38 activity, which consumes NAD+ outside cells.

Does restoring NAD+ reverse ageing effects?

Not established. Precursors raise NAD+-related markers, but durable clinical outcome data does not exist.

NAD+

NAD+ and Ageing: What Is Actually Established

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Tissue NAD+ levels decline with age across multiple species, and Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive this decline by increasing CD38 activity. Whether restoring NAD+ reverses age-related changes is a separate question and much less settled.

Key facts

Decline observed: Across tissues and species
Mechanism reported: Senescent cells increase CD38
Key paper: Covarrubias, Nat Metab 2020 (PMID 33199924)
Review: Covarrubias, Nat Rev Mol Cell Biol 2021
Restoration benefit: Not established in humans
Human outcome data: Limited

The observation

NAD+ levels fall with age in multiple tissues and multiple species. This is reasonably well replicated and is the empirical foundation the whole field rests on. It is a description of what happens, and on its own it says nothing about whether the decline causes anything.

The mechanism

Covarrubias and colleagues reported in 2020 that senescent cells promote tissue NAD+ decline by activating CD38 — the ectoenzyme that consumes NAD+ outside cells. That is a substantive advance, because it moves the story from a correlation with age to an identified consumer, and it connects NAD+ decline to cellular senescence, which is independently implicated in ageing.

Research material referenced

NAD+ 500mg — third-party HPLC tested

View — £49.99

Where the logic gets stretched

From a decline plus a mechanism, it is tempting to conclude that restoring NAD+ will reverse what the decline caused. That does not follow. Falling NAD+ may be a consequence of ageing processes rather than a driver of them, and increasing supply does not necessarily reduce the consumption that caused the fall. The 2021 Nature Reviews Molecular Cell Biology review is careful about this in ways downstream summaries usually are not.

What restoring it has actually shown

Precursor supplementation raises NAD+-related markers in at least some tissues in humans — this part is reasonably supported. What it has not shown is durable change in the clinical outcomes people care about. NADPARK was a phase I trial in Parkinson's disease; Orr's 2024 study in older adults was placebo-controlled and modest in scope. These are early-stage findings.

Why this literature attracts overstatement

A measurable molecule that declines with age, with an identified mechanism and an available intervention, is an unusually clean-looking story. Cleanness invites confidence. The gap between raising a biomarker and changing an outcome is where most of the overstatement lives, and it is the same gap that separates every surrogate endpoint from the thing it stands in for.

What is not claimed here

That NAD+ or its precursors slow ageing, extend life, or affect any condition in any person. The material supplied here is for laboratory research, holds no marketing authorisation, and the trial evidence described concerns precursors administered under clinical supervision.

Extended research context

The NAD+ deep dive

Deep dive: the compound in this catalogue that is not a peptide

NAD+ contains no amino acids and no peptide bonds. It is a dinucleotide - a nicotinamide nucleotide and an adenine nucleotide joined through a pyrophosphate bridge - which is the structural grammar of ATP and of RNA, not of a protein. It sits in a peptide catalogue because it reaches the same buyers, not because it belongs there. Saying so matters practically rather than pedantically: essentially all of the general handling guidance on this site is written for peptides and is the wrong guidance here. There is no sequence to verify, so purity by amino acid analysis is meaningless. There are no deletion sequences, because there is no stepwise coupling to produce them. Net peptide content, the figure that decides how much material a lyophilised peptide vial actually contains, has no analogue at all. Even the instruction that does carry over - dry, cold, dark - protects different chemistry, guarding glycosidic and pyrophosphate bonds rather than peptide bonds and methionine residues.

Deep dive: why the finished molecule is the least deliverable of the three

NAD+ carries two negatively charged phosphates and weighs 663.4 Da, and neither property is compatible with crossing a lipid bilayer. Extracellular NAD+ is also actively consumed: CD38 is an ectoenzyme with its active site facing outward, and Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive tissue NAD+ decline specifically by raising CD38 activity. Put those together and administered NAD+ is a molecule that cannot get in and is being degraded while it waits. Whatever follows most plausibly runs through its breakdown to smaller nicotinamide-containing species, which cells then take up and rebuild NAD+ from internally - which is to say, through exactly the precursors people otherwise take directly. This is why every substantial randomised trial in the field used nicotinamide riboside at 255.25 Da or nicotinamide mononucleotide at 334.22 Da rather than the coenzyme itself. The naming inverts the pharmacology: the finished molecule sounds like the most direct option and is the least.

Deep dive: good early evidence, and the gap that keeps getting closed rhetorically

The randomised human literature here is better than for most of this catalogue. NADPARK was a randomised phase I trial of nicotinamide riboside in Parkinson disease in Cell Metabolism. Orr and colleagues ran a randomised placebo-controlled study in older adults in GeroScience. Yoshino and colleagues published NMN and muscle insulin sensitivity in Science. These are real trials in real journals. What they measured, largely, is whether the intervention does what it is supposed to biologically - and raising a biomarker is not the same as changing an outcome. The step that gets taken rhetorically is from a decline that is real, through a mechanism that is identified, to a benefit that has not been demonstrated. Each link looks small; the chain is not. Nothing in this field approaches the scale of what settled the incretin questions, where TRIUMPH alone enrolled more than 5,800 participants with hard clinical endpoints.

Research applications

▸Cellular NAD+ metabolism and salvage pathway research
▸Sirtuin, PARP and CD38 enzyme activity studies
▸Redox biochemistry and NAD+/NADH ratio measurement
▸Cellular senescence and ageing biology research
▸Mitochondrial function and metabolic assay work
▸Comparative precursor uptake and conversion studies

Handling checklist

✓Verify against CID 5892, 663.4 Da, C21H27N7O14P2 - not by sequence
✓Do not apply peptide purity or net peptide content logic - neither exists here
✓Store lyophilised, cold, dry and protected from light
✓Prepare solutions fresh; nucleotide bonds hydrolyse readily in water
✓Be aware NAD+ and NADH are separately quantifiable oxidation states
✓Identity is confirmed by mass and chromatography against a reference standard

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Applying peptide handling and purity guidance to NAD+

Fix: It is a dinucleotide with no peptide bonds. Sequence verification, protease concerns, disulfide chemistry and net peptide content are all inapplicable.

✗ Assuming administered NAD+ enters cells intact

Fix: Two negative phosphate charges and 663 Da prevent membrane crossing, and CD38 degrades it extracellularly. Effects most plausibly run through breakdown products.

✗ Reading precursor trial results as evidence for NAD+ itself

Fix: Every substantial randomised trial used NR or NMN. NAD+ has essentially no comparable human literature.

✗ Treating a biomarker increase as a demonstrated benefit

Fix: Raising NAD+-related markers is reasonably supported. Durable clinical outcome data does not exist.

✗ Taking a precursor's food supplement status as evidence of efficacy

Fix: Supplement frameworks assess safety for consumption, not efficacy, and permit no therapeutic claims.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does NAD+ really decline with age?: Yes — that observation is reasonably well replicated across tissues and species.
What causes the decline?: Covarrubias 2020 reported that senescent cells drive it by increasing CD38 activity, which consumes NAD+ outside cells.
Does restoring NAD+ reverse ageing effects?: Not established. Precursors raise NAD+-related markers, but durable clinical outcome data does not exist.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More NAD+ articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum